Edwards Lifesciences Corp. (EW) has received approval from the U.S. FDA for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. The KONECT device comes with the advanced RESILIA tissue, which incorporates integrity-preservation technology that may help improve valve durability.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Edwards Lifesciences Corp. (EW) has received approval from the U.S. FDA for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. The KONECT device comes with the advanced RESILIA tissue, which incorporates integrity-preservation technology that may help improve valve durability.

RTTNews | Jul 15, 2020 08:44AM EDT

08:43 Wednesday, July 15, 2020 (RTTNews.com) - Edwards Lifesciences Corp. (EW) has received approval from the U.S. FDA for the KONECT RESILIA aortic valved conduit, the first ready-to-implant solution for bio-Bentall procedures. The KONECT device comes with the advanced RESILIA tissue, which incorporates integrity-preservation technology that may help improve valve durability.

Daveen Chopra, Edwards' corporate vice president, surgical structural heart, said: "Because the typical patient is under the age of 60, advanced technologies such as the KONECT device with the RESILIA tissue might provide extended valve durability for a more active patient population."

Read the original article on RTTNews ( https://www.rttnews.com/3111279/edwards-announces-fda-approval-for-konect-resilia-aortic-valved-conduit-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved